A new AI approach is designed to flag when it is uncertain about whether metastatic non-small cell lung cancer patients will respond to first-line chemoimmunotherapy. By incorporating confidence levels into treatment-prediction workflows, the tool aims to reduce high-stakes decision errors in settings where false optimism can translate into avoidable toxicity.